New research published in the Journal of Physiology presents a breakthrough in the treatment of Restless Legs Syndrome (RLS).
RLS is a common condition of the nervous system that causes an overwhelming irresistible urge to move the legs. Patients complain of unpleasant symptoms such as tingling, burning and painful cramping sensations in the leg. More than 80% of people with RLS experience their legs jerking or twitching uncontrollably, usually at night.
Until now it was thought that RLS is caused by genetic, metabolic and central nervous system mechanisms. For the first time the researchers show that, in fact, it is not only the central nervous system but also the nerve cells targeting the muscles themselves that are responsible.
This new research indicates that the involuntary leg movements in RLS are caused by increased excitability of the nerve cells that supply the muscles in the leg, which results in an increased number of signals being sent between nerve cells.
Targeting the way messages are sent between nerve cells to reduce the number of messages to normal levels may help prevent the symptoms of RLS occurring. This could be achieved by new drugs that block the ion channels that are essential for the communication between nerve cells.
The research conducted by the University of Gottingen in conjunction with the University of Sydney and Vanderbilt University involved measuring the nerve excitability of motor nerve cells of patients suffering with RLS and healthy subjects.
The next step is to investigate the effect of different medications in patients and the effect on RLS.
Dirk Czesnik, corresponding author of the study, commented on the findings:
‘Patients who suffer from Restless legs syndrome complain of painful symptoms in the legs leading to sleep disturbances. The mechanisms for RLS are still not completely understood. We have shown that also the nerve cells supplying muscles in the leg are responsible and hereby additional drug treatments may be ahead targeting these nerve cells.’
The Latest on: Restless legs syndrome
via Google News
The Latest on: Restless legs syndrome
- Unexpected mental illnesses found in a spectrum of a rare genetic disorderon June 25, 2020 at 12:36 am
Premutation is also associated with medical and psychiatric problems such as migraines, hypertension, sleep apnea, restless legs syndrome, anxiety and depression. The study found that patients ...
- SKOR1 has a transcriptional regulatory role on genes involved in pathways related to restless legs syndromeon June 22, 2020 at 3:27 am
Restless legs syndrome (RLS) is a common sleep-related sensory-motor disorder. It is characterized by uncomfortable sensations in the legs during the evening or at night. The symptoms can be partially ...
- Restless Legs Syndrome Market Size 2020 Global Market Growth, Trends, Revenue, Share and Demands Research Reporton June 10, 2020 at 12:37 am
Is there a problem with this press release? Contact the source provider Comtex at [email protected] You can also contact MarketWatch Customer Service via our Customer Center. The MarketWatch ...
- Restless Legs Syndromeon June 9, 2020 at 5:00 pm
One goal of RLS therapy is to reduce its symptoms, including decreasing the number of nights with RLS symptoms, the severity of RLS symptoms, and nighttime awakenings. Another goal pertains to ...
- 10 Questions About Restless Legs Syndromeon June 8, 2020 at 5:00 pm
Who Gets Restless Legs Syndrome? About 10% of people have restless legs syndrome, also called RLS. About 2% to 3% of them have moderate to severe symptoms that affect their quality of life.
- US FDA grants breakthrough device designation to Noctrix Health’s wearable NTX100 Neuromodulation therapy to treat restless legs syndromeon June 4, 2020 at 9:00 am
has granted Breakthrough Device Designation for its wearable NTX100 Neuromodulation therapy designed for the treatment of adults with primary moderate-severe Restless Legs Syndrome (RLS) who are ...
- Pneumatic Compression Devices Are an Effective Therapy for Restless Legs Syndromeon June 3, 2020 at 5:00 pm
Background: Pharmacotherapy for restless legs syndrome (RLS) may be ineffective or complicated by side effects. Uncontrolled series using pneumatic compression devices (PCDs) have been shown to ...
- Noctrix Health granted FDA Breakthrough Device Designation for wearable Restless Legs Syndrome Therapyon June 2, 2020 at 7:08 am
has granted Breakthrough Device Designation for its wearable NTX100 Neuromodulation therapy designed for the treatment of adults with primary moderate-severe Restless Legs Syndrome (RLS ...
via Bing News